News Updates
More Articles
- MHRA approves Moderna's updated COVID-19 vaccine
- GSK myelofibrosis drug momelotinib gains FDA nod
- BioNTech, CEPI partner on mpox vaccine candidates
- Cure Genetics, Frametact ink neuro treatment deal
- Canton Biologics secures $41M in Series C funding
MHRA approves Moderna's updated COVID-19 vaccine
Moderna announced that its COVID-19 vaccine, Spikevax, which has been updated to target the XBB.1.5 Omicron variant, has gained the Medicines and Healthcare products Regulatory Agency approval for use in persons ages 6 months and older. The company also disclosed that it will decrease production of mRNA drug substances at Lonza's facility in Switzerland due to reduced post-pandemic demand of the vaccines. Reuters (9/19)
Read full article now.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!